S&P 500   3,426.92 (-1.63%)
DOW   28,195.42 (-1.44%)
QQQ   283.80 (-1.63%)
AAPL   115.98 (-2.55%)
MSFT   214.22 (-2.48%)
FB   261.40 (-1.70%)
GOOGL   1,529.95 (-2.41%)
AMZN   3,207.21 (-2.00%)
TSLA   430.83 (-2.01%)
NVDA   539.91 (-2.27%)
BABA   305.29 (-0.66%)
CGC   19.81 (+11.54%)
GE   7.29 (+0.00%)
MU   52.63 (+1.98%)
AMD   82.00 (-1.41%)
T   26.88 (-1.65%)
F   7.59 (-1.04%)
ACB   4.71 (+17.16%)
GILD   60.57 (-2.31%)
NFLX   530.72 (-0.01%)
BA   167.11 (-0.14%)
BAC   23.72 (-2.15%)
DIS   124.23 (-2.03%)
S&P 500   3,426.92 (-1.63%)
DOW   28,195.42 (-1.44%)
QQQ   283.80 (-1.63%)
AAPL   115.98 (-2.55%)
MSFT   214.22 (-2.48%)
FB   261.40 (-1.70%)
GOOGL   1,529.95 (-2.41%)
AMZN   3,207.21 (-2.00%)
TSLA   430.83 (-2.01%)
NVDA   539.91 (-2.27%)
BABA   305.29 (-0.66%)
CGC   19.81 (+11.54%)
GE   7.29 (+0.00%)
MU   52.63 (+1.98%)
AMD   82.00 (-1.41%)
T   26.88 (-1.65%)
F   7.59 (-1.04%)
ACB   4.71 (+17.16%)
GILD   60.57 (-2.31%)
NFLX   530.72 (-0.01%)
BA   167.11 (-0.14%)
BAC   23.72 (-2.15%)
DIS   124.23 (-2.03%)
S&P 500   3,426.92 (-1.63%)
DOW   28,195.42 (-1.44%)
QQQ   283.80 (-1.63%)
AAPL   115.98 (-2.55%)
MSFT   214.22 (-2.48%)
FB   261.40 (-1.70%)
GOOGL   1,529.95 (-2.41%)
AMZN   3,207.21 (-2.00%)
TSLA   430.83 (-2.01%)
NVDA   539.91 (-2.27%)
BABA   305.29 (-0.66%)
CGC   19.81 (+11.54%)
GE   7.29 (+0.00%)
MU   52.63 (+1.98%)
AMD   82.00 (-1.41%)
T   26.88 (-1.65%)
F   7.59 (-1.04%)
ACB   4.71 (+17.16%)
GILD   60.57 (-2.31%)
NFLX   530.72 (-0.01%)
BA   167.11 (-0.14%)
BAC   23.72 (-2.15%)
DIS   124.23 (-2.03%)
S&P 500   3,426.92 (-1.63%)
DOW   28,195.42 (-1.44%)
QQQ   283.80 (-1.63%)
AAPL   115.98 (-2.55%)
MSFT   214.22 (-2.48%)
FB   261.40 (-1.70%)
GOOGL   1,529.95 (-2.41%)
AMZN   3,207.21 (-2.00%)
TSLA   430.83 (-2.01%)
NVDA   539.91 (-2.27%)
BABA   305.29 (-0.66%)
CGC   19.81 (+11.54%)
GE   7.29 (+0.00%)
MU   52.63 (+1.98%)
AMD   82.00 (-1.41%)
T   26.88 (-1.65%)
F   7.59 (-1.04%)
ACB   4.71 (+17.16%)
GILD   60.57 (-2.31%)
NFLX   530.72 (-0.01%)
BA   167.11 (-0.14%)
BAC   23.72 (-2.15%)
DIS   124.23 (-2.03%)
Log in
NASDAQ:ORMP

Oramed Pharmaceuticals Stock Forecast, Price & News

$2.82
+0.14 (+5.22 %)
(As of 10/19/2020 12:00 AM ET)
Add
Compare
Today's Range
$2.69
Now: $2.82▼
$2.96
50-Day Range
$2.54
MA: $2.91▼
$3.51
52-Week Range
$2.32
Now: $2.82▼
$6.05
Volume268,697 shs
Average Volume132,496 shs
Market Capitalization$66.35 million
P/E RatioN/A
Dividend YieldN/A
Beta1.49
Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the use of orally ingestible capsules or pills for delivery of polypeptides. Its product portfolio includes ORMD-0801, an oral insulin capsule for the treatment of diabetes; and ORMD-0901, an oral glucagon-like peptide-1 analog capsule for the treatment of type 2 diabetes. It is also developing a weight loss treatment in the form of an oral leptin capsule. The company was formerly known as Integrated Security Technologies, Inc. and changed its name to Oramed Pharmaceuticals Inc. in April 2006. Oramed Pharmaceuticals Inc. was founded in 2002 and is based in New York, New York.
Read More
Oramed Pharmaceuticals logo

Beat the Market (BTM) Rank™

Analyst Opinion: 3.5Community Rank: 3.1Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank™

1.32 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ORMP
Previous Symbol
CUSIPN/A
CIK1176309
Webwww.oramed.com
Phone844-967-2633
EmployeesN/A

Debt

Debt-to-Equity RatioN/A
Current Ratio9.99
Quick Ratio9.99

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$2.70 million
Price / Sales24.57
Cash Flow$0.76 per share
Price / Cash Flow3.72
Book Value$1.12 per share
Price / Book2.52

Profitability

EPS (Most Recent Fiscal Year)$0.82
Net Income$-14,350,000.00
Net Margins-230.07%
Return on Equity-28.75%
Return on Assets-17.58%

Miscellaneous

Outstanding Shares23,527,000
Market Cap$66.35 million
Next Earnings Date11/25/2020 (Estimated)
OptionableOptionable
$2.82
+0.14 (+5.22 %)
(As of 10/19/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ORMP News and Ratings via Email

Sign-up to receive the latest news and ratings for ORMP and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Oramed Pharmaceuticals (NASDAQ:ORMP) Frequently Asked Questions

How has Oramed Pharmaceuticals' stock price been impacted by COVID-19?

Oramed Pharmaceuticals' stock was trading at $3.31 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, ORMP stock has decreased by 14.8% and is now trading at $2.82.
View which stocks have been most impacted by COVID-19.

Do Wall Street analysts recommend investors buy shares of Oramed Pharmaceuticals?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Oramed Pharmaceuticals in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Oramed Pharmaceuticals.

When is Oramed Pharmaceuticals' next earnings date?

Oramed Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, November 25th 2020.
View our earnings forecast for Oramed Pharmaceuticals.

How were Oramed Pharmaceuticals' earnings last quarter?

Oramed Pharmaceuticals, Inc. (NASDAQ:ORMP) released its quarterly earnings data on Tuesday, July, 7th. The biotechnology company reported ($0.10) earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.17) by $0.07. The biotechnology company earned $0.68 million during the quarter, compared to analysts' expectations of $0.69 million. Oramed Pharmaceuticals had a negative net margin of 230.07% and a negative return on equity of 28.75%.
View Oramed Pharmaceuticals' earnings history.

What price target have analysts set for ORMP?

2 brokers have issued twelve-month price targets for Oramed Pharmaceuticals' shares. Their forecasts range from $5.50 to $17.00. On average, they anticipate Oramed Pharmaceuticals' stock price to reach $11.25 in the next year. This suggests a possible upside of 298.9% from the stock's current price.
View analysts' price targets for Oramed Pharmaceuticals.

Who are some of Oramed Pharmaceuticals' key competitors?

Some companies that are related to Oramed Pharmaceuticals include Agile Therapeutics (AGRX), Affimed (AFMD), Kezar Life Sciences (KZR), Urovant Sciences (UROV), Metacrine (MTCR), Cassava Sciences (SAVA), Selecta Biosciences (SELB), CTI BioPharma (CTIC), OrganiGram (OGI), Neptune Wellness Solutions (NEPT), Arbutus Biopharma (ABUS), Scpharmaceuticals (SCPH), IMV (IMV), MediciNova (MNOV) and Aduro BioTech (ADRO).
View all competitors.

What other stocks do shareholders of Oramed Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Oramed Pharmaceuticals investors own include TransEnterix (TRXC), Compugen (CGEN), Sarepta Therapeutics (SRPT), Zynerba Pharmaceuticals (ZYNE), Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE), DURECT (DRRX), Opko Health (OPK), Pluristem Therapeutics (PSTI) and Palatin Technologies (PTN).

Who are Oramed Pharmaceuticals' key executives?

Oramed Pharmaceuticals' management team includes the following people:
  • Mr. Nadav Kidron, CEO, Pres & Exec. Director (Age 45)
  • Dr. Miriam Kidron, Chief Scientific Officer, Chief Medical & Technology Officer and Director (Age 79)
  • Ms. Hilla Eisenberg CPA, CFO, Treasurer & Sec. (Age 35)
  • Dr. Roy Eldor M.D., Ph.D., Chief Medical Advisor & Member of the Scientific Advisory Board

What is Oramed Pharmaceuticals' stock symbol?

Oramed Pharmaceuticals trades on the NASDAQ under the ticker symbol "ORMP."

How do I buy shares of Oramed Pharmaceuticals?

Shares of ORMP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Oramed Pharmaceuticals' stock price today?

One share of ORMP stock can currently be purchased for approximately $2.82.

How big of a company is Oramed Pharmaceuticals?

Oramed Pharmaceuticals has a market capitalization of $66.35 million and generates $2.70 million in revenue each year. The biotechnology company earns $-14,350,000.00 in net income (profit) each year or $0.82 on an earnings per share basis.

What is Oramed Pharmaceuticals' official website?

The official website for Oramed Pharmaceuticals is www.oramed.com.

How can I contact Oramed Pharmaceuticals?

Oramed Pharmaceuticals' mailing address is 1185 AVENUE SUITE 228, NEW YORK NY, 10036. The biotechnology company can be reached via phone at 844-967-2633 or via email at [email protected]

This page was last updated on 10/19/2020 by MarketBeat.com Staff
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.